QT Imaging Holdings, Inc.
Moat Score — QT Imaging Holdings, Inc.
Total Moat Score
9 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | QT Imaging holds multiple FDA 510(k) clearances for its whole-breast ultrasound tomography platform, including a March 2026 clearance for an enhanced tilted-transmitter configuration, representing real regulatory and engineering IP. It is a genuine barrier to entry, but it is narrower and less defensible than a broad patent estate, and the underlying tomography approach has an existing FDA-cleared predicate (Delphinus SoftVue). |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | QT Imaging has no cost advantage today — FY2025 gross margin actually fell to 45% from 54% because units built by its contract manufacturer carried higher costs, including tariffs and fees. As a small-volume manufacturer competing against Siemens, GE, and Hitachi's ABUS platforms, it lacks the purchasing and manufacturing scale to compete on cost. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | As a capital-equipment seller still building clinical adoption and lacking full third-party reimbursement coverage (only a Category III CPT code, effective 2027, exists so far), QT Imaging has limited ability to set premium pricing — its exclusive distributors negotiate committed volumes, suggesting price is a lever used to secure distribution rather than a source of margin strength. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 1 / 5 | There is essentially no network effect today: one installed scanner does not make another hospital's scanner more valuable. The planned QTI Cloud Platform with Intelerad and Olea Medical could eventually create a modest data/AI flywheel as the installed base grows, but this is forward-looking and unproven. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a hospital or imaging center purchases a QT Breast Scanner and trains radiologists and technologists on its interpretation, replacing that capital equipment is costly and disruptive — a real, if narrow, switching cost at the individual-site level given how small the installed base still is relative to mammography and ABUS infrastructure. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | The whole-breast ultrasound tomography niche is small and shared with well-capitalized competitors (Siemens, GE Healthcare, Hitachi in ABUS; Delphinus in tomography) that could materially outspend QT Imaging on R&D and distribution if they chose to prioritize the category, leaving little protection from efficient-scale dynamics. |